Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (10229)	5/1/2008 7:38:00 AM
From: Robohogs	Respond to of 10280

I thought same thing and looked to see what was hiding. EPS pretty good on adusted basis, crap on gaap basis but they did do several drug deals so understandable to need adjusted. Revs for Xop looked darn good to me while every other product looked like crap. Revs were light overall. EPS given revs was awesome. Drug deals look interesting. Pipe launched 3 INDS from Q4. Real data on 2 other drugs in next few quarters. Guidance ok. Cash still good. Of the deals, three were with Arrow. Jon